Seventy Years of Antipsychotic Development: A Critical Review

Area of Science:

• Psychopharmacology
• Schizophrenia Treatment
• Drug Development

Background:

• Antipsychotic medications (APMs) have seen limited efficacy gains since the 1950s.
• Current APMs primarily offer improved tolerability, not enhanced effectiveness in treating schizophrenia.
• Decades of research have failed to yield significantly more effective antipsychotic treatments.

Purpose of the Study:

• To critically review 70 years of antipsychotic drug development.
• To identify key factors hindering the advancement of more effective APMs.
• To propose future directions for antipsychotic research and development.

Main Methods:

• Literature review of antipsychotic development over seven decades.
• Analysis of factors contributing to the stagnation of APM efficacy.
• Examination of assessment tools, research criteria, funding, and clinical practices.

Main Results:

• Stagnation in APM efficacy due to multiple factors: flawed research criteria, limited understanding beyond the dopaminergic hypothesis, and inadequate clinical trial designs.
• Confusing classification of APMs and insufficient statistical measures for clinical significance impede progress.
• Suboptimal prescribing practices and high costs of newer medications further compromise treatment effectiveness.

Conclusions:

• Significant advancements in antipsychotic medication efficacy remain elusive despite 70 years of development.
• Addressing research, funding, and clinical practice issues is crucial for future progress.
• Improved tolerability and long-acting formulations represent key recent advancements, particularly for adherence.